NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Meeting Abstract
| Authors: | Wainberg, Z. A.; Melisi, D.; Macarulla, T.; Pazo-Cid, R.; Chandana, S. R.; De La Fouchardiere, C.; Dean, Andrew P.; Kiss, I.; Lee, W.; Goetze, T. O.; Van Cutsem, E.; Paulson, A. S.; Bekaii-Saab, T. S.; Pant, S.; Hubner, R.; Xiao, Z.; Chen, H.; Benzaghou, F.; O'Reilly, E. M. |
| Abstract Title: | NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) |
| Meeting Title: | 2023 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2023 Jan 19-21 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.4_suppl.LBA661 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: LBA661 -- Accession Number: 161485268 -- Entry Date: In Process -- Revision Date: 20230127 -- Publication Type: Article -- Supplement Title: 2/1/2023 Supplement 1 -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
